Monday, August 24, 2026
ExploreSearch
Via News
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
AI Leadership Exodus Rattles Investor Confidence Amid Capex Boom
High-profile departures at top AI labs — Brad Lightcap's exit from OpenAI and an unnamed researcher's departure from Alphabet/Google that triggered a share-price drop — are surfacing talent retention as a market risk factor even as hyperscalers pour record capital into AI infrastructure. The reaction shows investors treating key-person risk at frontier AI labs as material to valuation, a new fragility layered onto an otherwise bullish AI-driven capex cycle.
Our read on the data ›
Signals we're tracking
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Patterns we're watching ›
Where sources disagree
Broadcom Inc.
Both facts report EPS for Broadcom Inc. for the same fiscal period (Q1 2026) observed on the same date (2026-02-01). However, they report conflicting values: 1.5 USD per share vs 2.05 USD per share. This is a 37% difference for the identical metric and time period, not a value change over time.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,978
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,978 facts checked against source5,251 source documents archived
Work with this data → vianewsagency.com

Health & Pharma

1 article

Global Alopecia Areata Drug Market Targets 2036 Expansion as OX40L Inhibitors Enter Clinical Pipelines

Global Alopecia Areata Drug Market Targets 2036 Expansion as OX40L Inhibitors Enter Clinical Pipelines

The worldwide alopecia areata treatment market is forecast to expand significantly by 2036, driven by new drug classes including OX40L inhibitors and interleukin-targeting agents.<sup>1</sup> The autoimmune hair-loss condition affects millions across every region, but effective therapies have historically been scarce. Regulatory momentum in Europe, the US, and Asia-Pacific is accelerating as autoimmune drug approvals broaden.

LM Salvado•